Market News & Trends
Unilife Surges on Wearable Injector Devices Pact With Amgen
Unilife Corporation stock jumped more than 100% this morning after the company announced a new deal with Amgen to develop wearable injector devices. Pennsylvania-based Unilife…
US Demand for Drug Delivery Products to Reach $251 Billion
US Demand for Drug Delivery Products to Reach $251 Billion Demand for drug delivery products in the US is projected to increase 6.1%…
Haselmeier Self-Injection Devices Go Connected
Haselmeier has added connectivity to its devices portfolio with the announcement of its new Axis-D-Connect Disposable Pen Injector. Haselmeier has partnered with the Austrian Institute…
Nanosphere Announces $10-Million Registered Public Offering
Nanosphere, Inc. recently announced the pricing of a public offering of the company’s common stock with expected total gross proceeds of approximately $10 million. The…
Top Pharma Companies’ R&D Returns Continue to Slide
While the Research and Development (R&D) divisions of 12 leading pharmaceutical companies have progressed 306 assets into late-stage pipelines since 2010, with projected lifetime returns…
Abbott & UCSF Discover New Virus is Linked to Hepatitis C
Abbott and University of California San Francisco (UCSF) published research identifying a newly discovered human virus, known as human pegivirus 2 (HPgV-2), and proving it…
Neon Therapeutics & BMS Enter Clinical Trial Collaboration
Neon Therapeutics recently announced a clinical trial collaboration with Bristol-Myers Squibb. The collaboration will evaluate the combination of Neon Therapeutics’ proprietary personalized neoantigen vaccine, NEO-PV-01,…
Neovacs SA Signs Strategic Partnering Agreement With CKD Pharmaceutical
Neovacs recently announced the signature of an exclusive licensing agreement with Chong Kun Dang (CKD) Pharmaceutical Corp. (Seoul, South Korea) to market the IFNa-Kinoïd for…
Lightlake Therapeutics Receives Milestone Payment for Nasal Spray
Lightlake Therapeutics Inc. recently announced it has received a $2-million milestone payment from Adapt Pharma Limited. This milestone payment was triggered by the US FDA…
KemPharm Submits NDA for KP201/APAP & Requests Priority Review
KemPharm, Inc. recently announced it has submitted an NDA under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act for KP201/APAP to the US…
Egalet Submits NDA for Morphine Sulfate ER Tablets
Egalet Corporation recently announced the company has submitted an NDA for ARYMO ER (morphine sulfate) extended-release tablets for the management of pain severe enough to…
MedPharm Announces Formation of US Subsidiary & First Appointment
MedPharm recently announced the formation of its new US-based laboratories, MP Pharma Services Inc. With a targeted operational date in Q1 2016, the services offered…
MGB Biopharma Successfully Completes Phase I Clinical Trial
MGB Biopharma recently announced it has successfully completed a Phase I clinical trial of an oral formulation of its lead product, MGB-BP-3, which is being…
Protea Announces Biopharm Industry Collaboration With Agilent
Protea Biosciences Group, Inc. recently announced it is collaborating with Agilent Technologies, Inc. to address customer challenges within existing Biopharma bioanalytical workflows in order to…
Exostar Launches Cybersecurity Risk Assessment Solution
Exostar, whose cloud-based solutions help companies in aerospace and defense, life sciences, and healthcare mitigate risk and solve their identity and access challenges, recently announced…
Pharmaceutical Deals Crucial to Offsetting $2.5-Billion Cost of Developing a Novel Drug
With the average cost of getting a novel drug to market at almost $2.5 billion, and few products achieving blockbuster status, deal-making is becoming increasingly…
Celldex Therapeutics Initiates Phase I/II Study
Celldex Therapeutics, Inc. recently announced the initiation of an open-label, Phase I/II safety and tolerability study examining the investigational combination of varlilumab and Roche's atezolizumab…
Soligenix Announces Initiation of Pivotal Phase III Clinical Trial
Soligenix, Inc. recently announced that patient enrollment has been opened for its Phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating SGX301 (synthetic hypericin), as a…
Global Immunology Treatment Market Will Exceed $74 Billion by 2022
Despite the imminent patent expiry of many therapies, the global immunology treatment market is set to expand, from $61.5 billion in 2015 to reach $74.2…
Pharma Outsourcing M&As Set for Record Year in 2015
A drastic increase in Mergers and Acquisitions (M&A) activity propelled the value of pharmaceutical outsourcing deals from $9.9 billion in 2014 to nearly $17.6 billion…
